Moderna announced Thursday it will receive up to $54.3 million from a global vaccine partnership to fund its ongoing research ...

Moderna will get up to $54.3 million in funding from a global coalition to support late-stage development of its experimental ...

The fresh capital provides another shot for Moderna's candidate against bird flu, which earlier this year lost its government ...

Moderna’s seasonal influenza vaccine met its main goal in a large Phase 3 trial, reducing the risk of influenza-like illness in people 50 years and older by 27% compared with those given a marketed ...

An influenza vaccine candidate from Moderna showed promising results in a late-stage trial, bringing the drug maker one step closer to producing a combined flu-and-Covid shot. But as scrutiny builds ...

Moderna Inc. (NASDAQ:MRNA) is one of the best mid cap growth stocks to invest in now. On June 12, the US FDA expanded the approval for Moderna’s respiratory syncytial virus/RSV vaccine, mRESVIA ...

The vaccine, called mRNA-1010, was tested in a Phase 3 study in adults ages 50 and older. It worked better than a standard-dose flu vaccine, providing 26.6% more protection against the flu overall, ...

Moderna on Monday said its experimental mRNA-based flu vaccine produced a stronger immune response than a currently available shot in a late-stage trial, clearing a path forward for the product and ...

CHICAGO -- Moderna announced interim results of its Covid-19 vaccine for children younger than 6 on Wednesday. The company said two 25-microgram doses of its Covid-19 vaccine for children ages 6 ...